3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Lymphoid
2
Dermatologic
2
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
81
Colorectal Neoplasms
39
Stomach Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Liver Neoplasms
14
Neoplasms
11
Melanoma
11
Carcinoma, Renal Cell
11
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Transitional Cell
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Ovarian Neoplasms
7
Head and Neck Neoplasms
7
Cholangiocarcinoma
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Merkel Cell
5
Biliary Tract Neoplasms
5
Prostatic Neoplasms
4
Sarcoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Interventions
Gemcitabine
3
pembrolizumab
2
napabucasin
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
linifanib
1
durvalumab
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Pemetrexed
1
Paclitaxel
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
HhAntag691
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled